Home › Research › Inflammation and the immune system
Targeting neuroinflammation in Alzheimer's disease
Bronzuoli MR, Iacomino A, Steardo L, Scuderi C.. Journal of inflammation research, 2016-11-03
Topic: Amyloid, tau and blood-test diagnosis
Almost 47 million people suffer from dementia worldwide, with an estimated new case diagnosed every 3.2 seconds. Alzheimer's disease (AD) accounts for approximately 60%-80% of all dementia cases. Given this evidence, it is clear dementia represents one of the greatest global public health challenges.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016). Targeting neuroinflammation in Alzheimer's disease. Journal of inflammation research. https://doi.org/10.2147/jir.s86958
Vancouver
Bronzuoli MR, Iacomino A, Steardo L, Scuderi C. Targeting neuroinflammation in Alzheimer's disease. Journal of inflammation research. 2016. doi:10.2147/jir.s86958. PMID: 27843334.
BibTeX
@article{bronzuoli2016-27843334,
author = {Bronzuoli, M. R. and Iacomino, A. and Steardo, L. and Scuderi, C.},
title = {{Targeting neuroinflammation in Alzheimer's disease}},
journal = {Journal of inflammation research},
year = {2016},
doi = {10.2147/jir.s86958},
pmid = {27843334},
url = {https://doi.org/10.2147/jir.s86958}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Alzheimer's disease (AD) accounts for approximately 60%-80% of all dementia cases.
- Given this evidence, it is clear dementia represents one of the greatest global public health challenges.
- Currently used drugs alleviate the symptoms of AD but do not treat the underlying causes of dementia.
- Hence, a worldwide quest is under way to find new treatments to stop, slow, or even prevent AD.
Why it matters
This review states that currently used Alzheimer's drugs only alleviate symptoms and do not treat the underlying causes of dementia, and that a worldwide effort is under way to find treatments to stop, slow, or prevent the disease. It does not report any new treatment or cure.
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of inflammation research) |
| Journal's citation record | 1 / 4 | Journal of Inflammation Research: journal h-index 81 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 255 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 21.2 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 4 / 6 | Cited 12.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 3 / 4 | Cited 59 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Caterina Scuderi: h-index 33 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Sapienza University of Rome: institution h-index 1,145 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27843334) |
| Free to read | 2 / 2 | Free to read |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2147/jir.s86958
- PubMed: 27843334
- Original source →
- Free full text: Journal of Inflammation Research →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 26.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Inflammation and the immune system
Also in Inflammation and the immune system
138 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.